Sight Sciences Inc. (SGHT)

[RC_702]

It’s just hit $5.70

[RC_702]

It’s closing in on the target price

[RC_702]

Hopefully it will bounce back
It beat estimated revenue

[RC_702]

Hopefully it will bounce back

[Southern Gal]

Lots of trading post and premarket. Could be another good day. Earnings to be reported on 8/1

https://finance.yahoo.com/news/sight-sciences-report-second-quarter-200500099.html

[Southern Gal]

Looking awesome. Getting close to a 52 week high PPS. I'm up nearly 200% on my $2.98's.

TFSBIGWS!!!

[RC_702]

Do you think that hold is referring to not buying the stock? Is that a possibility?

I love the way you have to dialogue with inflammatory language.

[RC_702]

Do you think that hold is referring to not buying the stock? Is that a possibility?

I love the way you have to dialogue with inflammatory language.

[Southern Gal]

Only a fool would listen to an analyst who advises holding a stock that's trading $2.25 ABOVE their price target.

CURRENT PRICE $7.95
Price Target $5.70
ANALYST RATING:
HOLD

[Southern Gal]

Oh NO!!!

47,780 shares? Out of the millions they own????

The world is coming to an end!!!

https://finance.yahoo.com/quote/SGHT/insider-roster/

[RC_702]

Re: the buyout you speculated about

I’m guessing that Alison Bouerlein, CFO
Jeremy Hayden , David Badawi, CTO, Paul Badawi CEO, and Sam Park CTO who are officers of sght did not know about the merger either.
They all sold shares July 1, 2 2024

47,780 shares at 5.42 to 6.21 average price per share

[Southern Gal]

they're

[Southern Gal]

Oh no, not another UP day!! How many am I supposed to endure?

UP $0.49
+6.27%

ANOTHER 11 month high closing PPS!

Boy- those analysts sure do know what their talking about, don't they!?!?

[RC_702]

I guess they don’t know about the buyout:


According to marketbeat:


UPSIDE/ DOWNSIDE
27.1% Downside
$5.70 Price Target

SHORT INTEREST
Bearish
4.09% of Float Sold Short

ANALYST RATING
Hold
2.00 Rating Score

(Sight Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 5 hold ratings, and 1 sell rating.)

INSIDER TRADING
Selling Shares
$290,061 Sold Last Quarter

Overall marketrank
0.50 out of 5 stars

[RC_702]

What happened?

Sight Sciences sets terms for IPO, to raise up to $160.5 million
Published: July 8, 2021 at 6:37 a.m. ET

Sight Sciences Inc. has set terms of its initial public offering, which could value the California-based ophthalmology and optometry company at up to $971.7 million. The company is looking to raise up to $160.54 million, as it is offering 6.98 million shares in the IPO, which is expected to price between $20 and $23 a share.

[Southern Gal]

LOL

Up nearly 3%

Closed at the 11 month high pps

[Southern Gal]

lol

[Southern Gal]

I put more weight into my own projection- that SGHT will be acquired by a larger optical device company, like Alcon, against whom SGHT was recently awarded damages for patent infringement.

https://www.healio.com/news/ophthalmology/20240430/sight-sciences-awarded-34-million-in-patent-infringement-case-against-alcon

[RC_702]

Here’s where I got the information:

Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · IEX Real-Time Price · USD

Price Target
5.60 (-27.18%)

[RC_702]

Not my analysis, just researching what various experts have suggested about the potential stock movements of sght.

Three different sources have said not to buy and multiple sources have said year price around $6.

What do you think about the fact that the projected profitability is three years away at best?

[RC_702]

Perhaps JP Morgen and others that dumped all their stock was because of this:

Financial Efficiency
Return on equity (ROE) is -44.50% and return on invested capital (ROIC) is -38.09%.

I believe that would be a good call

[Southern Gal]

That makes so much sense

7 analysts have a target of $5.60, which is $2 BELOW the current PPS, and yet, the 7 analysts recommending holding?

So- they recommend holding so as to lock in a 30% LOSS?
BRILLIANT!!!!

RC_702
Re: None
Monday, July 15, 2024 9:25:07 AM
Post# of 80 Go
Analyst Forecast
According to 7 analysts, the average rating for SGHT stock is "Hold." The 12-month stock price forecast is $5.6, which is a decrease of -26.41% from the latest price.

Price Target
$5.6
(-26.41% downside)
Analyst Consensus: Hold[/quote]

[RC_702]

Analyst Forecast
According to 7 analysts, the average rating for SGHT stock is "Hold." The 12-month stock price forecast is $5.6, which is a decrease of -26.41% from the latest price.

Price Target
$5.6
(-26.41% downside)
Analyst Consensus: Hold

[RC_702]

Before you buy stock in Sight Sciences, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Sight Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

[RC_702]

Perhaps JP and others dumped their shares because of this:

Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.

I guess that’s what you could consider a good call

[RC_702]

Sorry, but it was not my call. I’m not an expert but I can read what the experts have stated

I guess you’re referring to JP Morgan dumping all of their shares recently being a good call

[Southern Gal]

GOOD CALL!!!

12 Month Price Target usd 6.10
Based on 4 analysts
Price Volatility. High
Last updated: 6/12/2024

On 6/12 the PPS closed @ $6.86

On Friday the PPS closed @ $7.61

That's more than a 10% gain in 1 month

Oh, and BTW, a 25% gain for my $2.98 shares.

[Southern Gal]

it seems they were all wrong to sell and forecast lower
Closed on Friday at an 11 month high PPS

I'm laughing all the way to the bank
1 YEAR CHART

[RC_702]

Or perhaps it was:

Operating Income % is Gross Profit minus Operating Expenses. Shown as a percentage of Revenue. A good indicator of profitability. Higher is better.

SGHT OI
2023 - 77.06 %
2022 - 117.70%

Or:

Net Profit % shows how much of each dollar in Revenue translates into Profit. Shown as a percentage of Revenue. Higher is better.

SGHT Net Profit
2023 -68.53%
2022 - 120.90%

And analysts say that they are not going to be profitable for at least three years

[RC_702]

Perhaps it was this:

12 Month Price Target usd 6.10
Based on 4 analysts
Price Volatility. High
Last updated: 6/12/2024
Industry Recommendation. Hold

[RC_702]

What do they know about the company that made them dump the stock recently?

JPMorgan Chase decreased stake by 12.86% to <0.01% of portfolio.
DE Shaw&Co
D. E. Shaw & Co. decreased stake by 7.52% to <0.01% of portfolio.
Morgan Stanley
Morgan Stanley decreased stake by 20.27% to <0.01% of portfolio.

[Southern Gal]

LMAO!!!

UP 30% since your post.

[RC_702]

Earnings Trend: SGHT is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.

[RC_702]

Insider trading , why did:
D1 capital partners LD on 26 Dec23
Sell $16,712,931 of sight sciences?
Entity: company
Shares: 2,852,036
Max Price: $5.86

[RC_702]

Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.
Yahoo finance June 14, 2024

[RC_702]

Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.
Yahoo finance June 14, 2024

[Monksdream]

SGHT under $10

[Southern Gal]

Wow- somebody took a bunch of profit in the last minutes. First down day is quite a while

[Southern Gal]

And another up day.

[Southern Gal]

First time SGHT closed above $7 in over 6 months!!!

[Southern Gal]

She broke through seven dollars. very strong volume today. So bright I gotta wear shades

[Southern Gal]

Good news...

creates big gains. Blue skies ahead. My $2.98's have doubled+

[Southern Gal]

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced the publication of the twelve-month results from the SAHARA trial.

Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops (“Restasis”) had additional clinically meaningful improvements in the signs and symptoms of dry eye disease (“DED”) when crossed over to TearCare. These improvements persisted for six months through month twelve without continued Restasis use.

“Phase 2 of the RCT again demonstrates the clinical effectiveness of TearCare. It also shows that effectiveness appears to be the same whether or not a patient has had prior treatment with Restasis, demonstrating that similar results could be expected when TearCare is used as a primary or secondary treatment for DED,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences.

Phase 1 of the SAHARA RCT included 345 subjects at 19 sites in 11 states randomized 1:1 to either TearCare or Restasis1. In Phase 2 of the SAHARA RCT, 163 patients who had been randomized and treated with Restasis during phase 1 were crossed over to TearCare at the six-month visit and followed for six months through Month 12 of the study.

Data from the first six months of the SAHARA RCT demonstrated that TearCare, an interventional eyelid procedure for DED, was superior at all measured time points to twice daily use of Restasis for the improvement of tear break up time (“TBUT”), the trial’s primary dry eye signs endpoint and a key measure of tear stability1. TearCare was superior to Restasis in multiple other objective measures of dry eye, and demonstrated clinically meaningful improvements in several symptoms that matched or surpassed Restasis at all measured time points.

The aim of phase 2, undertaken in months six through twelve, was to demonstrate that cessation of Restasis followed by a single TearCare procedure would result in improved signs and symptoms for patients beyond what was achieved with six months of Restasis.

[Southern Gal]

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) study data. This new analysis evaluated the association between the severity of glaucoma and the intraocular pressure ("IOP") and medication outcomes for patients treated with the OMNI Surgical System ("OMNI"). OMNI enables a procedure intended to restore aqueous outflow of glaucomatous eyes by addressing the three areas of outflow resistance associated with the disease.

The findings suggest that ab interno canaloplasty coupled with trabeculotomy using OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma patients as it was in mild and moderate glaucoma patients. This data challenges the belief that advanced disease stage is a barrier to successful treatment outcomes for minimally invasive glaucoma surgery ("MIGS").

"There had been some debate about the efficacy of MIGS in advanced glaucoma patients, with speculation that prolonged disease may cause irreversible harm to the distal outflow pathway," said Dr. Jaime E. Dickerson, Jr., Vice President of Medical and Clinical Affairs at Sight Sciences. "The current study suggests that treatment with OMNI technology, which has a strong safety profile and proven durability, is still effective in patients with more extensive visual field damage."

ROMEO was an Institutional Review Board ("IRB") approved retrospective case series conducted at eleven ophthalmology practices in the United States. Participants were mainly primary open-angle glaucoma patients (122 of 129, or 95%) who had undergone the implant-free OMNI procedure, which has been cleared by the FDA for canaloplasty followed by ab interno trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma, either combined with cataract surgery or as a standalone procedure.

Eyes were categorized based on visual field mean deviation ("MD"), with participants assigned to a group with severity rated as mild (n=79, median MD -2.7 dB), moderate (n=42, median MD -8.0 dB) or advanced (n=6, median MD -13.3). The study compared outcomes at 12 months.

Key findings reported in the study include:

Significant reductions in both IOP and IOP-reducing medications were observed.
The majority of eyes (70%) experienced a reduction in IOP at Month 12, with most achieving levels of 18 mmHg or less (92%).
The percentage of IOP reduction was consistent across severity groups, with month 12 mean IOP ranging between 14 mmHg and 16 mmHg.
Medication reductions were observed across all severity groups, with the majority of patients showing a reduction of at least 1 medication (50% to 69%), indicating the effectiveness of the treatment approach.
Regression analysis found no significant relationship between month 12 IOP and visual field loss, suggesting treatment outcomes were consistent irrespective of disease severity.
"Clinical trials and real-world results continue to demonstrate favorable OMNI treatment outcomes across different stages of glaucoma," said Paul Badawi, Co-Founder and CEO of Sight Sciences. "These findings reinforce our dedication to offering effective treatment options for glaucoma patients at every stage of the disease and also fuel our initiatives to continue reimagining eyecare with transformative technology and an interventional mindset."

[Southern Gal]

Looking awesome! Excellent quarterly conference call. PPS is strong and the future should be most favorable. +$6 is a few pennies away. +$10 this summer seems reasonable.

[Southern Gal]

Great news!

[Southern Gal]

News of a settlement? Basis for yesterday's gain?
04/23/2024 STATEMENT Offer of Proof Regarding the Economic Comparability of the Glaukos Settlement Agreement by Alcon Inc.,

[Southern Gal]

Beautiful close above $6.

[Southern Gal]

Jury selection begins pretty soon between Alcon and sight sciences. SGHT has very good sales and clinically proven efficacy. Seems to me that the quickest fix for Alcon’s problems is to buy sight sciences, lock, stock, and barrel. Alcon gets two great products and whatever sight sciences has in development. Perhaps most importantly, an acquisition makes Alcon's legal problems go away. Alcon's is looking at huge retroactive and ongoing royalties due to Sight Sciences, if the jury decides against Alcon.

[Invest-in-America]

SGHT: The potential expansive applications for their tech. go way beyond mere 'DRY EYES', per se.